These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 7994790)
1. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report. Uekado Y; Hirano A; Shinka T; Ohkawa T Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790 [TBL] [Abstract][Full Text] [Related]
2. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer. Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130 [TBL] [Abstract][Full Text] [Related]
3. Prevention of the Recurrence of Superficial Bladder Cancers: Intravesical Instillation of Bacillus Calmette-guerin Versus Bacillus Calmette-guerin Plus Epirubicin. Tozawa K; Okamura T; Yamada Y; Hayashi Y; Sasaki S; Kohri K Asian Pac J Cancer Prev; 2000; 1(3):217-220. PubMed ID: 12718668 [TBL] [Abstract][Full Text] [Related]
4. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group. Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group. Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788 [TBL] [Abstract][Full Text] [Related]
7. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637 [TBL] [Abstract][Full Text] [Related]
8. Trial with bacillus Calmette-Guérin and epirubicin combination in the prophylaxis of superficial bladder cancer. Erol A; Ozgür S; Basar M; Cetin S Urol Int; 1994; 52(2):69-72. PubMed ID: 8178379 [TBL] [Abstract][Full Text] [Related]
9. Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer. Bono AV; Lovisolo JA; Saredi G Eur Urol; 2000 Apr; 37(4):478-83. PubMed ID: 10765080 [TBL] [Abstract][Full Text] [Related]
10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
12. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group. Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783 [TBL] [Abstract][Full Text] [Related]
13. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer]. Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430 [TBL] [Abstract][Full Text] [Related]
14. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group. Raitanen MP; Lukkarinen O Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711 [TBL] [Abstract][Full Text] [Related]
15. [Intravesical bacillus Calmette-Guerin instillation therapy in superficial bladder cancers--clinical study on prognostic factors]. Shinka T; Hirano A; Uekado Y; Ohkawa T Nihon Hinyokika Gakkai Zasshi; 1990 Mar; 81(3):425-32. PubMed ID: 2359220 [TBL] [Abstract][Full Text] [Related]
16. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect]. Yamamoto T; Hagiwara M; Nakazono M; Yamamoto H Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):997-1001. PubMed ID: 2214478 [TBL] [Abstract][Full Text] [Related]
18. Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin. Shinka T; Hirano A; Uekado Y; Ohkawa T Br J Urol; 1990 Jul; 66(1):35-9. PubMed ID: 2393797 [TBL] [Abstract][Full Text] [Related]
19. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin]. Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120 [TBL] [Abstract][Full Text] [Related]
20. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence]. Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]